First AD

Second AD

combination therapies for high-risk renal cell carcinoma (RCC) patients 

Triple Combination Therapies in RCC: Clinical Trial Insights 

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Genitourinary Cancers

EXE-22-OSD1273 - /clinical/genitourinary-cancer

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma

Peer Exchange

Huntsman Cancer Institute at the University of Utah 

Cancer Centers

Partner

The University of Texas MD Anderson Cancer Center

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

Imaging and Staging Considerations in Renal Cell Carcinoma 

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen 

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma 

Comparing Treatment Combinations in Renal Cell Carcinoma 

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC 

Sequencing and Second-Line Therapy in RCC: Patient Scenario 

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma 

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment  